VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023

VYNE Therapeutics Inc.

Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.
Option term for Oral BETi Compounds extended to Feb 28, 2023; VYNE to pay In4Derm £300,000 by June 30, 2022.
Upon discovery of two Oral BETi Compounds with specified molecular profile, VYNE to pay In4Derm additional £850,000.
Previous Phase 1b segment showed statistically significant reduction in ADSI score and pruritus with FMX114 vs vehicle.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.